1. |
NICE issues guidance for sibutramine in obesity |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
Pharma companies wage war against anthrax |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 3-4
Carmen Innes,
Preview
|
|
摘要:
As the war against bioterrorism heats up, so another war begins amongst the pharma companies who manufacture antibacterials against anthrax. As of 1 November, 4 deaths in the US have been attributed to deliberately-spread anthrax; not a large number by any means, but enough to create such terror among Americans that demand for antibacterials to prevent anthrax has skyrocketed. Bayer AG's ciprofloxacin ['Cipro'] was approved by the US FDA in August last year for the treatment and prophylaxis of inhalation anthrax, the most fatal form of the disease, and has been the most popular antibacterial used in this outbreak. With tens of thousands of people currently taking the drug to prevent anthrax, the US Centers for Disease Control (CDC) is now recommending prophylaxis with ciprofloxacin or doxycycline, to achieve a better balance in the types of drugs used and to decrease the chance of antibacterial resistance. Bayer has a patent on ciprofloxacin until 2003, leading companies who manufacture generic versions of the drug to demand a relaxation of patent laws. Drug companies who make other antibacterials similar to ciprofloxacin, but not FDA-approved for anthrax, are stating that they would make the drugs free of charge to the US government if they were to be approved for the disease.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
Lower risk of PONV with propofol TIVA |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
The fall and rise of economic studies of bipolar disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 7-8
Mark Greener,
Preview
|
|
摘要:
Scan the literature, search MEDLINE, attend major psychiatry conferences and you'll find several studies estimating the burden of illness, or the relative cost effectiveness of treatments, in schizophrenia, depression and anxiety-spectrum disorders. Traditionally, bipolar disorder ('manic depression') attracted relatively little attention from health economists. Now, a new study has estimated the annual burden of illness that bipolar disorder places on UK society.1The analysis was presented at the 7th World Congress of Biological Psychiatry held earlier this year and has now been accepted for publication in the British Journal of Psychiatry. The study could offer a baseline for considering management costs as new drugs are introduced for this potentially devastating condition.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
Omeprazole less costly than surgery for GORD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
Towards improved treatments for anthrax |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Tiotropium bromide: setting new standards in COPD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1312,
2001,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
The new anticholinergic agent tiotropium bromide is an effective bronchodilator in chronic obstructive pulmonary disease (COPD) and appears to be superior to the long-acting β2-agonist salmeterol in a number of disease measures, according to data released at the European Respiratory Society meeting [Berlin, Germany; September 2001]. In a 6-month study by researchers from Boehringer Ingelheim, tiotropium bromide ['Spiriva'] significantly improved lung function, as measured by FEV1, relative to salmeterol and placebo. Dyspnoea and health-related quality of life (HRQL) were also improved by tiotropium bromide, compared to placebo, whereas salmeterol showed no significant benefits over placebo. Tiotropium bromide acts via prolonged M3-receptor antagonism and offers an advantage over standard therapies for COPD in that it is administered once daily, rather than twice daily, thereby improving patient compliance. The agent, approved in Switzerland last month, is the first once-daily therapy for COPD to hit the market.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|